Ratings Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-03-14 EDT			5-day change	1st Jan Change
111.44 ^USD	-0.99%		-5.08%	+20.65%

03-13	Nurix Therapeutics Appoints Roy D. Baynes to Its Board of Directors	CI
03-12	Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option	CI

Summary: Gilead Sciences, Inc.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company has a good ESG score relative to its sector, according to MSCI.

Highlights: Gilead Sciences, Inc.

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Gilead Sciences, Inc.

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings Chart: Gilead Sciences, Inc.

Source: Surperformance

ESG chart: Gilead Sciences, Inc.

Source: MSCI

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals	Valuation	Revisions of Fundamental Estimates	Capi.($)
	GILEAD SCIENCES, INC.				139B
	ELI LILLY AND COMPANY				731B
	JOHNSON & JOHNSON				392B
	ABBVIE INC.				374B
	NOVO NORDISK A/S				343B
	ROCHE HOLDING AG				277B
	MERCK & CO., INC.				239B
	ASTRAZENECA PLC				240B
	NOVARTIS AG				215B
	AMGEN INC.				169B
	Average				311.82B
	Weighted average by Cap.

See all sector ratings

Investor

Trader

ESG MSCI

AAA

Financials

Sales growth

EPS Growth

Profitability

Net margin

Financial Health

Valuation

P/E ratio

EV/REVENUE

EV/EBITDA

PBR

Yield

Revisions

1 year Revenue revision

4 months Revenue revision

1 months Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analysts' recommendations

4m Revision of opinion

Potential Price Target

4m Target Price Revision

12m Target Price Revision

Business Predictability

Earnings quality

Analyst Coverag

Divergence of analysts' recommendations

Divergence of Target Price

Divergence of analysts' opinions

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes